Form 4: Brainstorm Cell Therapeutics CEO Receives Stock Award

Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, was granted 120,000 shares of restricted stock on January 1, 2025, according to a Form 4 filing.

Summary

• Chaim Lebovits, the President and CEO of Brainstorm Cell Therapeutics, received 120,000 shares of restricted stock on January 1, 2025.
• The shares were awarded under the Issuer's 2014 Global Share Option Plan.
• 50% of the award will vest on the six-month anniversary of the grant date, and the remaining 50% will vest on the eighteen-month anniversary, contingent upon continued employment.
• Following the transaction, Lebovits directly owns 200,960 shares of common stock.
• Lebovits may also be deemed the beneficial owner of 133,389 shares held by ACCBT Corp. and 4,470 shares held by ACC International Holdings Ltd.

Sentiment

Score: 7

Explanation: The document indicates standard executive compensation practices, which is generally viewed neutrally to positively. The vesting schedule is a positive sign of commitment.

Positives

• The stock award aligns the CEO's interests with those of the shareholders, incentivizing him to drive long-term value creation.
• The vesting schedule encourages continued service and commitment from the CEO.

Risks

• The CEO's departure before the vesting dates would result in the forfeiture of unvested shares.

Industry Context

Stock awards are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Stakeholder Impact

• The stock award could positively impact shareholders by incentivizing the CEO to improve company performance.
• Employees may view the award as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Brainstorm Cell Therapeutics, BCLI, Chaim Lebovits, CEO, stock award, restricted stock, Form 4, insider transaction, beneficial ownership